CSL and Alentis Partnered on Drug Development
The companies have entered a global deal to co-develop lixudebart for the treatment of various kidney and liver diseases.
Updated on Oct. 4, 2026 in Healthcare
Live Poll
Do you believe corporate partnerships are effectively accelerating the development of treatments for rare diseases?
CSL and Alentis Therapeutics formed a global partnership to co-develop and commercialize the monoclonal antibody lixudebart. The agreement aims to accelerate treatment development for conditions including AAV-RPGN, FSGS, and PSC.
Why it matters
This collaboration allows CSL to expand its global nephrology franchise by leveraging Alentis's expertise in claudin-1 targeting. By pooling resources, the firms intend to advance multiple disease indications simultaneously.
CSL will pay Alentis an initial US$355 million, with Alentis eligible for up to US$1.2 billion in milestone payments. Global profits will be shared at a 55 percent split for CSL and 45 percent for Alentis.
The players
CSL
Headquartered in Melbourne, Australia, this global biotechnology company focuses on vaccines and specialized therapies.
Alentis Therapeutics
Based in Basel, Switzerland, this clinical-stage biotechnology firm specializes in developing treatments for organ fibrosis and cancer.
The details
CSL will fully fund the ongoing Phase 2 RENAL trial and upcoming Phase 3 development programs. The partnership covers lixudebart, a monoclonal antibody designed to target claudin-1 to address significant medical needs in kidney and liver health.
Timeline
October 5, 2026: CSL and Alentis announced their global collaboration agreement.
Market Landscape
This deal signals a broader trend of large pharmaceutical firms utilizing partnerships to build specialized franchises in complex fields like nephrology. It positions CSL to compete more aggressively in the liver and kidney disease markets through external innovation.
This partnership aims to accelerate the availability of potential new therapies for serious liver and kidney conditions. While it does not impact current retail pricing, patients with these chronic illnesses may see more clinical trial options as development moves forward.
The takeaway
Collaborative agreements like this are critical for balancing the high costs of drug development with the need for specialized medical expertise. Readers should note that while this accelerates research, the path to commercial availability for new therapies remains years away.
Further reading
Learn more about the latest innovations in the medical sector on our Healthcare page.
Source note: This article includes information reported by The Queenslander.
Live Poll
Do you believe corporate partnerships are effectively accelerating the development of treatments for rare diseases?
